Amputation

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants

Retrieved on: 
Monday, April 8, 2024
Failure, De novo, Health, Prevalence, Infection, Arthroplasty, Patient, Trauma, Mortality, Bacteria, Osteoporosis, Food and Drug Administration, Neoplasm, Amputation, FDA, Onko, Pharmaceutical industry

PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants. Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.

Key Points: 
  • PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants.
  • Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.
  • "Implant contamination is a growing concern to the orthopaedic surgical community," said Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College, Endowed Professor of Orthopaedic Oncology and Director, Musculoskeletal Oncology at Rush Cancer Center.
  • The Onkos technology is a significant innovation and another option to help reduce local bacterial load on the implant."

Travis Mills to Deliver Commencement Address at 125th Husson Graduation

Retrieved on: 
Monday, March 25, 2024
Health, Amputation, Veteran, Relaxation, Science, Humanities, Education, Husson University, Cross Insurance Center, Family, Nursing

BANGOR, MAINE, March 25, 2024 (GLOBE NEWSWIRE) -- Husson University is pleased to announce that Retired United States Army Staff Sergeant Travis Mills will deliver the address at the 2024 Husson University Commencement on Saturday, May 4, 2024.

Key Points: 
  • BANGOR, MAINE, March 25, 2024 (GLOBE NEWSWIRE) -- Husson University is pleased to announce that Retired United States Army Staff Sergeant Travis Mills will deliver the address at the 2024 Husson University Commencement on Saturday, May 4, 2024.
  • Husson’s 125th Commencement Ceremony will take place at 10:30 a.m. at the Cross Insurance Center in Bangor.
  • Mills is a motivational speaker, actor, author and an advocate for veterans and amputees.
  • For more information about educational opportunities that can lead to personal and professional success, visit Husson.edu .

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 22, 2024
Diagnosis, Research, U.S. FDA, Peripheral artery disease, Infection, Patent, Buddha's hand, Evaluation, PAD, Journal, Sale, University, Doctor of Philosophy, Efficacy, Priority review, Regenerative medicine, Clinical trial, Trial of the century, Vascular surgery, HAV, Hospital, Injury, Nationwide Children's Hospital, HUMA, FACS, Amputation, Food, FDA, Defense, BLA, PDUFA, Pharmaceutical industry

DURHAM, N.C., March 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Key Points: 
  • There was no revenue for either the fourth quarter of 2023 or the fourth quarter of 2022, and there was no revenue for the year ended December 31, 2023.
  • Research and development expenses were $20.2 million for the fourth quarter of 2023, compared to $15.0 million for the fourth quarter of 2022, and were $76.6 million for the year ended December 31, 2023, compared to $63.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $6.0 million for the fourth quarter of 2023, compared to $5.8 million for the fourth quarter of 2022, and were $23.5 million for the year ended December 31, 2023, compared to $22.9 million for the year ended December 31, 2022.
  • The 2023 increases in net loss resulted from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.

CEO of Innovative Outcomes, Inc., (OTC:UBQU) Offers Open Letter to Shareholders and Investors

Retrieved on: 
Wednesday, March 13, 2024
Growth, Caregiver, Diabetes, Patient, Death, CBD, Insurance, Wound healing, OTC, CO, Hemp, Future, Amputation, Government, Health, Nursing

DENVER, CO, March 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ubiquitech Software Corp. (OTC: UBQU) a dynamic and innovative software development company, is pleased to offer this open letter to shareholders and investors from the CEO of its new subsidiary Innovative Outcomes, Inc. (Innovative Outcomes) a prominent player in the multi-billion-dollar medical wound care industry.

Key Points: 
  • DENVER, CO, March 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ubiquitech Software Corp. (OTC: UBQU) a dynamic and innovative software development company, is pleased to offer this open letter to shareholders and investors from the CEO of its new subsidiary Innovative Outcomes, Inc. (Innovative Outcomes) a prominent player in the multi-billion-dollar medical wound care industry.
  • CEO of Innovative Outcomes, Inc. Kevin Lamb: For the last 25 years my passion has focused on the medical industry; specifically, individuals who suffer from debilitating diabetes and vascular diseases.
  • This focus on “patients first” fulfills the mission of Innovative Outcomes, bridging the gap between medical professionals, insurance companies, and patients.
  • Follow Ubiquitech Software Corp, Inc. to learn more about Innovative Outcomes and stay informed about Company developments and growth:

Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease

Retrieved on: 
Thursday, March 21, 2024
Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Elixir, Peripheral artery disease, CLTI, Medicine, Risk, Patient, PAD, Mortality, Motion, Life, BTK, Amputation, Marketing, FDA, Circulant matrix, Food, Pharmaceutical industry

The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.

Key Points: 
  • The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.
  • "The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease,” said Motasim Sirhan, CEO at Elixir Medical.
  • “We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease.”
    The FDA Breakthrough Device Designation accelerates the review process for novel technologies designed to address an unmet medical need.
  • Devices that receive breakthrough designation must meet rigorous standards for device safety and effectiveness in order to be authorized for marketing.

Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal

Retrieved on: 
Thursday, April 4, 2024
DFI, Diabetes, Sepsis, Infection, Incidence, Risk, Ulcer, Patient, Mortality, Adjunct (grammar), University of Washington, University, Manuscript, Standard of care, Quality of life, Diabetic foot, Skin, Safety, Political moderate, Amputation, Medicine, Biofilm, Pharmaceutical industry

and VANCOUVER, BC, April 4, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.

Key Points: 
  • and VANCOUVER, BC, April 4, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.
  • The manuscript titled "Topical Pravibismane as Adjunctive Therapy for Moderate or Severe Diabetic Foot Infections: A Phase 1b Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial" is available for free download at International Wound Journal's website ( https://doi.org/10.1111/iwj.14817 ).
  • This therapeutic objective is currently being assessed in our recently completed, 12-week Phase 2 study in moderately infected, chronic diabetic foot ulcers."
  • The published manuscript describes in detail the Phase 1b study that was designed to evaluate the safety and efficacy of pravibismane in managing moderate or severe chronic diabetic foot ulcer infections.

Encompass Health announces preliminary plans to build a 50-bed inpatient rehabilitation hospital in San Antonio

Retrieved on: 
Wednesday, April 3, 2024
EHC, Encompass Health, Amputation, Patient, Hospital, Quality of life, Stroke, Brain, Tetraplegia, DSM-IV codes, Pharmacy, Injury, Nursing, Physician, Rehabilitation

BIRMINGHAM, Ala., April 3, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced preliminary plans to build a freestanding, 50-bed inpatient rehabilitation hospital in San Antonio.

Key Points: 
  • BIRMINGHAM, Ala., April 3, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced preliminary plans to build a freestanding, 50-bed inpatient rehabilitation hospital in San Antonio.
  • The hospital, located in Westover Hills, will serve patients recovering from debilitating illnesses and injuries, including strokes and other neurological disorders, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions.
  • In addition to 24-hour nursing care, the hospital will offer physical, occupational and speech therapies to restore functional ability and quality of life.
  • "We are excited to bring inpatient rehabilitation services to the Westover Hills community," said Frank Brown, president of Encompass Health's Southwest region.

Vantage Foundation partners Instituto Claret to uplift underprivileged in Brazil

Retrieved on: 
Wednesday, March 27, 2024
SAO, NEOM, Amputation, Environment, Health, Partnership, Education, Child, Food security, McLaren Technology Centre, Social consciousness, UNHCR, Filippo Grandi, Nursing

SAO PAULO, March 27, 2024 /PRNewswire/ -- Vantage Foundation is pleased to announce its partnership with Instituto Claret, a reputable charitable organisation in Brazil.

Key Points: 
  • SAO PAULO, March 27, 2024 /PRNewswire/ -- Vantage Foundation is pleased to announce its partnership with Instituto Claret, a reputable charitable organisation in Brazil.
  • Instituto Claret offers a range of programmes including support for children, families, violence prevention, homeless assistance, food security, and vocational training.
  • This initiative with Instituto Claret is part of a series of programmes run by Vantage Foundation , underscoring the organisation's ongoing commitment to making a positive impact worldwide.
  • "Vantage Foundation remains steadfast in our commitment to creating positive change in meaningful ways around the world," expressed Steven Xie, Executive Director of Vantage Foundation.

Vantage Foundation partners Instituto Claret to uplift underprivileged in Brazil

Retrieved on: 
Wednesday, March 27, 2024
SAO, NEOM, Amputation, Environment, Health, Partnership, Education, Child, Food security, McLaren Technology Centre, Social consciousness, UNHCR, Filippo Grandi, Nursing

SAO PAULO, March 27, 2024 /PRNewswire/ -- Vantage Foundation is pleased to announce its partnership with Instituto Claret, a reputable charitable organisation in Brazil.

Key Points: 
  • SAO PAULO, March 27, 2024 /PRNewswire/ -- Vantage Foundation is pleased to announce its partnership with Instituto Claret, a reputable charitable organisation in Brazil.
  • Instituto Claret offers a range of programmes including support for children, families, violence prevention, homeless assistance, food security, and vocational training.
  • This initiative with Instituto Claret is part of a series of programmes run by Vantage Foundation , underscoring the organisation's ongoing commitment to making a positive impact worldwide.
  • "Vantage Foundation remains steadfast in our commitment to creating positive change in meaningful ways around the world," expressed Steven Xie, Executive Director of Vantage Foundation.

Music, Advanced Medicine, and Robotics Merge in Groundbreaking UltraCon 2024 Ultrasound Presentations

Retrieved on: 
Tuesday, March 26, 2024
Malta at War Museum, Amputation, FACP, AIUM, Permeability, Medtronic, MD, Robotics, American Institute, Creativity, Music, Liquid biopsy, Machine learning, Health, Rehabilitation, Medical device

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- The upcoming UltraCon 2024 conference, organized by the American Institute of Ultrasound in Medicine (AIUM), is set to spotlight groundbreaking advancements in medical technology with keynotes from industry luminaries Dr. Omar Ishrak and Dr. Gil Weinberg. This premier event, taking place from April 6–10 in Austin, Texas, will draw professionals from across the medical imaging spectrum to discuss the future of ultrasound technology and its applications.

Key Points: 
  • "Their groundbreaking work exemplifies the spirit of innovation that drives our field forward, offering new ways to enhance patient care and improve lives."
  • "The future of ultrasound technology lies at the intersection of innovation and patient care," stated Dr. Ishrak.
  • "Ultrasound will play a significant role in shaping the future of healthcare, and at UltraCon 2024, I look forward to exploring how advancements in imaging can redefine what's possible in diagnostics and treatment."
  • For a list of all UltraCon 2024 exhibitors, please visit this link .